EU PERSPECTIVES - Europe has learned to count the people extreme heat kills. It has barely begun to count what that heat does to the minds of those who live through it. Read more

EU PERSPECTIVES - Screens are not the main culprit behind Europe's youth mental health crisis. They merely amplify problems that already exist, and ignoring the crisis now could cost the EU €1.68tn over the next decade. Read more

EU PERSPECTIVES - The EU has agreed its landmark law against drug shortages. The regulator who has to deliver it just put a number on the work ahead. Read more

EURACTIV - Austria provisionally reimburses the new anti-amyloid Alzheimer's therapies, disease-modifying antibodies such as lecanemab and donanemab – and runs treatment centres in every province. On paper, it is a model rollout. Read more

EURACTIV - For the first time, medicine can slow Alzheimer's disease, but the new drugs only work early, and across Europe most people are still diagnosed too late or not at all. Mercè Boada Rovira, one of Spain's most experienced dementia clinicians, told a policy meeting in Rome what it would take to change that. Read more

EURACTIV - The EU's pharmaceutical reforms are not law yet, but for Belgium, the cost of waiting is already real. The pharma package faces a final vote this autumn, and most rules only bite around 2028, while the Critical Medicines Act could apply soon after 2026. Read more

EU PERSPECTIVES - The revision of the EU's medical device rules is exposing a wider disagreement over how AI should be regulated in healthcare. While industry and some lawmakers argue for less duplication between the Medical Device Regulation and the AI Act, others warn against giving the Commission too much discretion over future requirements. ...

EU PERSPECTIVES - That question overshadowed the Irish presidency's first appearance before European Parliament's Health Committee. While Dublin promoted competitiveness, innovation and resilience, lawmakers repeatedly steered the debate back to one issue: the budget. Read more

EURACTIV - Ten years after the first etanercept biosimilar was launched in Europe, regulators, registry data and practising clinicians have arrived at a common position: approved biosimilars work as well as the medicines they copy, and they widen access to them. Read more

EU PERSPECTIVES - A group of lawmakers wants to establish a new fund for health innovation, aimed at ensuring faster access to breakthrough medicines and diagnostics. It should be built into the next EU long-term budget. The main idea? Preventing the dilution of funds in the wider competitiveness spending. Read more